[1] Taubes, G. (2008) The bacteria fight back. Science, 321, 356-361. doi:10.1126/science.321.5887.356
[2] Klevens, R.M., Morrison, M.A., Nadle, J., Petit, S., Gershman, K., Ray, S., et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA, 298, 1763-1771. doi:10.1001/jama.298.15.1763
[3] Bancroft, E.A. (2007) Antimicrobial resistance: It’s not just for hospitals. JAMA, 298, 1803-1804. doi:10.1001/jama.298.15.1803
[4] D’Agata, E.M., Webb, G.F., Horn, M.A., Moellering, R.C. and Ruan, S. (2009) Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clinical Infectious Diseases, 48, 274-284. doi:10.1086/595844
[5] Farley, J.E. (2008) Epidemiology, clinical manifestations, and treatment options for skin and soft tissue infection caused by community-acquired methicillin-resistant Staphylococcus aureus. Journal of the American Academy of Nurse Practitioners, 20, 85-92. doi:10.1111/j.1745-7599.2007.00290.x
[6] Wright, G.D. (2010) Antibiotic resistance: Where does it come from and what can we do about it? BMC Biology, 8, 123. doi:10.1186/1741-7007-8-123
[7] D’Costa V.M., King, C.E., Kalan, L., Morar, M., Sung, W.W., Schwarz, C., et al. (2011) Antibiotic resistance is ancient. Nature, 477, 457-461. doi:10.1038/nature10388
[8] Bennett, P.M. (2008) Plasmid encoded antibiotic resistance: Acquisition and transfer of antibiotic resistance genes in bacteria. British Journal of Pharmacology, 153, S347-S357. doi:10.1038/sj.bjp.0707607
[9] Ohnishi, M., Golparian, D., Shimuta, K., Saika, T., Hoshina, S., Iwasaku, K., et al. (2011) Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrobial Agents and Chemotherapy, 55, 3538-3545. doi:10.1128/AAC.00325-11
[10] Dethlefsen, L., Fall-Ngai, M. and Relman, D.A. (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature, 449, 811-818. doi:10.1038/nature06245
[11] Blaser, M.J. and Kirschner, D. (2007) The equilibria that allow bacterial persistence in human hosts. Nature, 449, 843-849. doi:10.1038/nature06198
[12] Blaser, M.J. and Falkow, S. (2009) What are the consequences of the disappearing human microbiota? Nature Reviews Microbiology, 7, 887-894. doi:10.1038/nrmicro2245
[13] Curtis, M.M. and Way, S.S. (2009) Interleukin-17 in host defense against bacterial, mycobacterial and fungal pathogens. Immunology, 126, 177-185. doi:10.1111/j.1365-2567.2008.03017.x
[14] Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., et al. (2007) Phenotypic and functional features of human Th17 cells. The Journal of Experimental Medicine, 204, 1849-1861. doi:10.1084/jem.20070663
[15] Blaser, M.J., Chen, Y. and Reibman, J. (2008) Does Helicobacter pylori protect against asthma and allergy? Gut, 57, 561-567. doi:10.1136/gut.2007.133462
[16] Koenen, H.J., Smeets, R.L., Vink, P.M., van Rijssen, E., Boots, A.M. and Joosten, I. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood, 112, 2340-2352. doi:10.1182/blood-2008-01-133967
[17] Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R. and Gordon, J.I. (2007) The human microbiome project. Nature, 449, 804-810. doi:10.1038/nature06244
[18] Jukes, T. (2012) Antibiotics in animal feeds and production. Bioscience, 22, 526-534. doi:10.2307/1296312
[19] Albrich, W.C., Baughman, W., Schmotzer, B. and Farley, M.M. (2007) Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clinical Infectious Diseases, 44, 1569-1576. doi:10.1086/518149
[20] Regev-Yochay, G., Dagan, R., Raz, M., Carmeli, Y., Shainberg, B., Derazne, E., et al. (2004) Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. JAMA, 292, 716-720. doi:10.1001/jama.292.6.716
[21] Regev-Yochay, G., Bogaert, D., Malley, R., Hermans, P.W., Veenhoven, R.H., Sanders, E.A., et al. (2008) Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children? Clinical Infectious Diseases, 47, 289-291. doi:10.1086/589573
[22] Rasko, D.A., Moreira, C.G., Li, D.R., Reading, N.C., Ritchie, J.M., Waldor, M.K., et al. (2008) Targeting QseC signaling and virulence for antibiotic development. Science, 321, 1078-1080. doi:10.1126/science.1160354
[23] Schneider, D.S. and Ayres, J.S. (2008) Two ways to survive infection: What resistance and tolerance can teach us about treating infectious diseases. Nature Reviews Immunology, 8, 889-895. doi:10.1038/nri2432
[24] Lamkanfi, M. (2011) Emerging inflammasome effector mechanisms. Nature Reviews Immunology, 11, 213-220. doi:10.1038/nri2936
[25] Chu, J., Thomas, L.M., Watkins, S.C., Franchi, L., Nunez, G. and Salter, R.D. (2009) Cholesterol-dependent cytolysins induce rapid release of mature IL-1beta from murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner. Journal of Leukocyte Biology, 86, 1227-1238. doi:10.1189/jlb.0309164
[26] Dostert, C., Guarda, G., Romero, J.F., Menu, P., Gross, O., Tardivel, A., et al. (2009) Malarial hemozoin is a Nalp3 inflammasome activating danger signal. The Public Library of Science One, 9, e6510.
[27] Gurcel, L., Abrami, L., Girardin, S., Tschopp, J., van der Goot, F.G. (2006) Caspase-1 activation of lipid metabolic pathways in response to bacterial poreforming toxins promotes cell survival. Cell, 126, 1135-1145. doi:10.1016/j.cell.2006.07.033
[28] Thomas, P.G., Dash, P., Aldridge, J.R., Ellebedy, A.H., Reynolds, C., Funk, A.J., et al. (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity, 30, 566-575. doi:10.1016/j.immuni.2009.02.006
[29] Cassel, S.L., Eisenbarth, S.C., Lyer, S.S., Sadler, J.J., Colegio, O.R., Tephly, L.A., et al. (2008) The NALP3 inflammasome is essential for the development of silicosis. Proceeding of the National Academy Sciences of the USA,105, 9035-9040. doi:10.1073/pnas.0803933105
[30] Dostert, C., Petrilli, V., van Bruggen, R., Steele, C., Mossman, B.T. and Tschopp, J. (2008) Innate immune activation through NALP3 inflammasome sensing of asbestos and silica. Science, 320, 674-677. doi:10.1126/science.1156995
[31] Hornung, V., Bauernfeind, F., Halle, A., Samstad, E.O., Kono, H., Rock, K.L., et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology, 9, 847- 856. doi:10.1038/ni.1631
[32] Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Petrilli, V., et al. (2009) Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. American Journal of Respiratory and Critical Care Medicine, 179, 903-913. doi:10.1164/rccm.200808-1274OC
[33] Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O’Rourke, K., Roose-Girma, M., et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature, 440, 228-232. doi:10.1038/nature04515
[34] Salminen, A., Ojala, J., Suuronen, T., Kaarniranta, K. and Kauppinen, A. (2008) Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer’s pathology. Journal of Cellular and Molecular Medicine, 12, 2255-2262. doi:10.1111/j.1582-4934.2008.00496.x
[35] Yamasaki, K., Muto, J., Taylor, K.R., Cogen, A.L., Audish, D., Bertin, J., et al. (2009) NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. The Journal of Biological Chemistry, 284, 12762-12771. doi:10.1074/jbc.M806084200
[36] Elinav, E., Strowig, T., Kau, A.L., Henao-Mejia, J., Thaiss, C.A., Booth, C.J., et al. (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell, 145, 745-757. doi:10.1016/j.cell.2011.04.022
[37] Thacker, J.D., Sassi-Gaha, S., Stephens, C., Purohit, M., Rest, R.F. and Artlett, C.M. (2012) NLRP3 Inflammasome is a target for development of broad-spectrum anti-infective drugs. Antimicrobial Agents Chemotherapy, 56, 1921-1930. doi:10.1128/AAC.06372-11
[38] Henan-Mejia, I., Elinav, E., Strowig, T. and Flavell, R.A. (2012) Inflammasomes: Far beyond inflammation. Nature Immunology, 13, 321-324. doi:10.1038/ni.2257
[39] Franchi, L., Mu?oz-Planillo, R. and Nú?ez, G. (2012) Sensing and reacting to microbes through inflammasomes. Nature Immunology, 13, 325-332. doi:10.1038/ni.2231
[40] Zitvogel, L., Kepp, O., Galluzzi, L. and Kroemer, G. (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nature Immunology, 13, 343-351. doi:10.1038/ni.2224